QUALITY GUARANTEE

If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.

Quality test failed? Free replacement or full refund.

Off-spec? Free replacement or full refund.

FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →

FDA PCAC: 7 peptides under review. Read →

SS-31 / Elamipretide

Name: SS-31 / Elamipretide
Brand: Vialdyne
SKU: ss-31

Mitochondria-targeted tetrapeptide (Szeto-Schiller)

≥ 99.0%CAS 736992-21-5Mitochondrial Peptides

Overview

SS-31, also known as Elamipretide (MTP-131, Bendavia), is a cell-permeable Szeto-Schiller tetrapeptide that concentrates selectively in the inner mitochondrial membrane through reversible association with cardiolipin. By stabilising cardiolipin-cytochrome-c interactions it is studied for its effect on electron-transport-chain efficiency and reactive-oxygen-species generation, which is why mitochondrial, cardiac, and neurodegeneration research models are the dominant demand context. Vialdyne releases lyophilised SS-31 acetate to a ≥99.0% HPLC main-peak specification, with a batch COA available from sales. Every released lot comes with its batch COA covering RP-HPLC purity and mass-spec identity; peptide-content assay, related substances, water (Karl Fischer), counter-ion, residual solvents and endotoxin are available on request and listed on the COA when tested. ESI-MS identity and the raw chromatogram are documented on the same lot for labs assembling a CMC or reference-standard dossier.

Applications & buyer fit

Mitochondrial-targeted peptides ship primarily to research labs studying OXPHOS, ROS biology, and mitochondrial dysfunction in disease models. The lipophilic / cationic character that drives mitochondrial accumulation also makes these peptides somewhat oxidation-prone in solution, working stocks should be prepared fresh or held at -80 °C rather than -20 °C when the workflow permits.

How SS-31 / Elamipretide is sourced

Sourced for

Research into OXPHOS, ROS biology, and mitochondrial dysfunction in disease models

Buyer fit

academic and contract research laboratories

Documentation that ships

Certificate of Analysis (COA)
HPLC Chromatogram
Mass-spec identity (ESI-MS)
Sequence verification (LC-MS/MS)
Oxidative-stability data
Bacterial endotoxin (LAL, USP <85>)
Bioburden screening
SDS / MSDS

Procurement note: The cationic / lipophilic character makes these peptides oxidation-prone in solution; working stocks are best held cold and prepared fresh.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS: 736992-21-5
Molecular Formula: C32H49N9O5
Molecular Weight: 639.80 g/mol
Sequence: D-Arg-Dmt-Lys-Phe-NH2
Appearance: White to off-white lyophilized powder
Purity (HPLC): ≥ 99.0%
Strength: 5 mg – 50 mg
Packaging: 10 vials/kit · base pack (multiples of 10)
Half-life: ≈ 0.5-1 hour
MOQ: On request
Lead time: 10–18 days
Storage: 2–8°C, protect from light

Nasal spray listing · US inventory

SS-31 / Elamipretide is also listed in this catalog as a nasal spray solution.

Listed contents: 5 mg
Fill: 10 mL or 20 mL bottle
MOQ: 10 bottles per content and fill
Dispatch: Within the United States, from US inventory

A black 10 mL nasal spray bottle, spray pump under a clear protective cap — The 10 mL spray bottle

Batch COAs and test reports

Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.

Batch COA

SS-31 / Elamipretide 5 mg

HPLC purity · MS identity

Batch COA

Full, clear copy from sales

Batch COA

SS-31 / Elamipretide 10 mg

HPLC purity · MS identity

Batch COA

Full, clear copy from sales

Batch COA

SS-31 / Elamipretide 50 mg

HPLC purity · MS identity

Batch COA

Full, clear copy from sales

Third-party report

SS-31 50 mg

HPLC purity · MS identity

Third-party laboratory, Tianjin, China

Full, clear copy from sales

Independent test fails? Full refund. How it works

Browse all COAs and reports

Regulatory note

Investigational compound; not approved as a finished drug in any jurisdiction. Sold as a research-use-only reference material, not for human or veterinary use.

Selected literature

Thompson WR, Hornby B, Manuel R, Bradley E, Laux J, Carr J, Vernon HJ. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021;23(3):471-478.
Thompson WR, Manuel R, Abbruscato A, Carr J, Campbell J, Hornby B, Vaz FM, Vernon HJ. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024;26(7):101138.
Karaa A, Bertini E, Carelli V, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101(3):e238-e252.
Sabbah HN, Gupta RC, Kohli S, et al. Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circ Heart Fail. 2017;10(8):e004389.
Ehlers JP, Khanani AM, Wykoff CC, et al. ReCLAIM-2: a randomized phase II clinical trial evaluating elamipretide in age-related macular degeneration, geographic atrophy growth, visual function, and ellipsoid zone preservation. Ophthalmol Sci. 2025;5(1):100621.
Chavez JD, Tang X, Campbell MD, et al. Mitochondrial protein interaction landscape of SS-31. Proc Natl Acad Sci U S A. 2020;117(26):15363-15373.

Frequently asked questions

What makes SS-31 mitochondria-targeted?▾

SS-31 carries an alternating aromatic-cationic motif (the Szeto-Schiller design) that lets the peptide cross the plasma membrane and then concentrate in the inner mitochondrial membrane through reversible binding to cardiolipin, a phospholipid unique to that membrane. This targeting is what separates SS-31 from peptides that act at the cell surface, and it is the basis for its use in mitochondrial-bioenergetics research.

Is SS-31 the same as Elamipretide and Bendavia?▾

Yes. SS-31 is the original Szeto-Schiller laboratory designation; Elamipretide (MTP-131) is the international nonproprietary name used in clinical development, and Bendavia is a former development code. All refer to the same D-Arg-Dmt-Lys-Phe-NH2 tetrapeptide (Dmt = 2,6-dimethyltyrosine). The released-batch COA lists CAS 736992-21-5 and the ESI-MS identity so the molecule can be cross-referenced unambiguously.

Can SS-31 / Elamipretide be ordered as a nasal spray?▾

Yes. SS-31 / Elamipretide is listed as a nasal spray solution (5 mg), filled in 10 mL or 20 mL bottles, with an MOQ of 10 bottles per content and fill. It is dispatched within the United States from US inventory; send an inquiry for current availability.

What if my own lab test shows the product is out of specification?▾

Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.

Related peptides

Buyers who view SS-31 / Elamipretide also ask about:

16-mer

MOTS-c (Human)

≥99.0%

Mitochondrial-derived peptide

CAS: 1627580-64-6
Vial: 10 mg–40 mg

Nasal spray listed

MOQ on requestGet quote →

See full catalog

SS-31 / Elamipretide

Mitochondria-targeted tetrapeptide (Szeto-Schiller)

≥ 99.0%CAS 736992-21-5Mitochondrial Peptides

Overview

Applications & buyer fit

How SS-31 / Elamipretide is sourced

Sourced for

Research into OXPHOS, ROS biology, and mitochondrial dysfunction in disease models

Buyer fit

academic and contract research laboratories

Documentation that ships

Certificate of Analysis (COA)
HPLC Chromatogram
Mass-spec identity (ESI-MS)
Sequence verification (LC-MS/MS)
Oxidative-stability data
Bacterial endotoxin (LAL, USP <85>)
Bioburden screening
SDS / MSDS

Procurement note: The cationic / lipophilic character makes these peptides oxidation-prone in solution; working stocks are best held cold and prepared fresh.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS: 736992-21-5
Molecular Formula: C32H49N9O5
Molecular Weight: 639.80 g/mol
Sequence: D-Arg-Dmt-Lys-Phe-NH2
Appearance: White to off-white lyophilized powder
Purity (HPLC): ≥ 99.0%
Strength: 5 mg – 50 mg
Packaging: 10 vials/kit · base pack (multiples of 10)
Half-life: ≈ 0.5-1 hour
MOQ: On request
Lead time: 10–18 days
Storage: 2–8°C, protect from light

Nasal spray listing · US inventory

SS-31 / Elamipretide is also listed in this catalog as a nasal spray solution.

Listed contents: 5 mg
Fill: 10 mL or 20 mL bottle
MOQ: 10 bottles per content and fill
Dispatch: Within the United States, from US inventory

Batch COAs and test reports

Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.

Batch COA

SS-31 / Elamipretide 5 mg

HPLC purity · MS identity

Batch COA

Full, clear copy from sales

Batch COA

SS-31 / Elamipretide 10 mg

HPLC purity · MS identity

Batch COA

Full, clear copy from sales

Batch COA

SS-31 / Elamipretide 50 mg

HPLC purity · MS identity

Batch COA

Full, clear copy from sales

Third-party report

SS-31 50 mg

HPLC purity · MS identity

Third-party laboratory, Tianjin, China

Full, clear copy from sales

Independent test fails? Full refund. How it works

Browse all COAs and reports

Regulatory note

Investigational compound; not approved as a finished drug in any jurisdiction. Sold as a research-use-only reference material, not for human or veterinary use.

Selected literature

Thompson WR, Hornby B, Manuel R, Bradley E, Laux J, Carr J, Vernon HJ. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021;23(3):471-478.
Thompson WR, Manuel R, Abbruscato A, Carr J, Campbell J, Hornby B, Vaz FM, Vernon HJ. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024;26(7):101138.
Karaa A, Bertini E, Carelli V, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101(3):e238-e252.
Sabbah HN, Gupta RC, Kohli S, et al. Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circ Heart Fail. 2017;10(8):e004389.
Ehlers JP, Khanani AM, Wykoff CC, et al. ReCLAIM-2: a randomized phase II clinical trial evaluating elamipretide in age-related macular degeneration, geographic atrophy growth, visual function, and ellipsoid zone preservation. Ophthalmol Sci. 2025;5(1):100621.
Chavez JD, Tang X, Campbell MD, et al. Mitochondrial protein interaction landscape of SS-31. Proc Natl Acad Sci U S A. 2020;117(26):15363-15373.

Frequently asked questions

What makes SS-31 mitochondria-targeted?▾

Is SS-31 the same as Elamipretide and Bendavia?▾

Can SS-31 / Elamipretide be ordered as a nasal spray?▾

What if my own lab test shows the product is out of specification?▾

Related peptides

Buyers who view SS-31 / Elamipretide also ask about:

16-mer

MOTS-c (Human)

≥99.0%

Mitochondrial-derived peptide

CAS: 1627580-64-6
Vial: 10 mg–40 mg

Nasal spray listed

MOQ on requestGet quote →

See full catalog